Harrow HROW is set to give its latest quarterly earnings report on Thursday, 2025-05-08. Here's what investors need to know before the announcement. Analysts estimate that Harrow will report an ...

Harrow's relaunch of Triesence, a preservative-free corticosteroid, addresses a critical unmet need in ophthalmology, offering safer and more effective treatment options for eye care professionals ...

Wasatch Micro Cap Value Strategy featured stocks like Harrow, Inc. (NASDAQ:HROW) in the fourth quarter 2023 investor letter. Headquartered in Nashville, Tennessee, Harrow, Inc. (NASDAQ:HROW ...

Harrow reported a $20 million loss for the first half of 2024, doubling from the previous year. Increased competition from generics and new drugs will squash margins. Harrow's recent strategy ...

NASHVILLE, Tenn., March 11, 2025--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the execution of a five-year strategic supply and ...

Harrow (NASDAQ:HROW) is set to give its latest quarterly earnings report on Thursday, 2025-05-08. Here's what investors need to know before the announcement. Analysts estimate that Harrow will ...